DeepMed Research

INSTITUTO GRIFOLS SA

🇪🇸Spain

Country: 🇪🇸Spain

Ownership: Subsidiary

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease

Phase 2

Completed

Conditions: Alzheimer's Disease

Interventions: Biological: Albumin 5%
Biological: Albumin 20%
Biological: Immunoglobulin

First Posted Date: 2012-03-22

Last Posted Date: 2019-07-31

Lead Sponsor: Instituto Grifols, S.A.

Target Recruit Count: 347

Registration Number: NCT01561053

Locations: 🇺🇸
Howard University, Washington, District of Columbia, United States
🇺🇸
Wesley Neurology Clinic, Cordova, Tennessee, United States
🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States

and more 37 locations

Effects on Plasma Exchange on Functional Capacity of Serum Albumin, Circulatory Dysfunction, Renal and Cerebral Function in Cirrhotic Patients With "Acute-on-chronic Liver Failure"

Not Applicable

Completed

Conditions: Liver Cirrhosis
Liver Failure

Interventions: Procedure: Plasma exchange with albumin

First Posted Date: 2010-09-15

Last Posted Date: 2019-02-07

Lead Sponsor: Instituto Grifols, S.A.

Target Recruit Count: 12

Registration Number: NCT01201720

Locations: 🇪🇸
Hospital Clínic of Barcelona, Barcelona, Spain

Efficacy and Safety of Niuliva® for the Prevention of Hepatitis B Virus Recurrence in Newly Orthotopic Liver Transplant Recipients

Phase 3

Completed

Conditions: Hepatitis B
Liver Transplantation

Interventions: Drug: Hepatitis B immune globulin

First Posted Date: 2010-05-26

Last Posted Date: 2016-02-25

Lead Sponsor: Instituto Grifols, S.A.

Target Recruit Count: 15

Registration Number: NCT01131065

Locations: 🇮🇹
Az. Ospedaliera Universitaria di Padova, Padova, Italy
🇮🇹
A.O.U. Policlinico Università di Modena e Reggio Emilia, Modena, Italy
🇮🇹
Az. Ospedaliera S.Giovanni Battista di Torino, Torino, Italy

and more 1 locations

Effects of Long Term Albumin 20% Administration in Patients With Cirrhosis and Ascites.

Phase 4

Completed

Conditions: Cirrhosis
Ascites

Interventions: Drug: Albumin

First Posted Date: 2009-08-31

Last Posted Date: 2019-06-26

Lead Sponsor: Instituto Grifols, S.A.

Target Recruit Count: 33

Registration Number: NCT00968695

Locations: 🇪🇸
Hospital del Mar, Barcelona, Spain
🇪🇸
Hospital Universitario Ramón y Cajal, Madrid, Spain
🇪🇸
Hospital Clínic of Barcelona, Barcelona, Spain

and more 3 locations

Efficacy and Safety of Intramuscular HBIG Grifols for the Prevention of Recurrence After Liver Transplantation

Phase 2

Completed

Conditions: Hepatitis B, Chronic

Interventions: Drug: intramuscular hepatitis B virus immune globulin

First Posted Date: 2009-05-08

Last Posted Date: 2009-05-08

Lead Sponsor: Instituto Grifols, S.A.

Target Recruit Count: 18

Registration Number: NCT00895713

Locations: 🇮🇹
Ospedaliera Molinette, Torino, Italy
🇮🇹
Cisanello Hospital. (University of Pisa)., Pisa, Italy

Evaluation of Serum Levels and Pharmacokinetics of a New Hepatitis B Immune Globulin Following Liver Transplantation

Phase 3

Completed

Conditions: Hepatitis B, Chronic

Interventions: Drug: Specific intravenous anti-hepatitis B immunoglobulin

First Posted Date: 2009-02-06

Last Posted Date: 2009-02-06

Lead Sponsor: Instituto Grifols, S.A.

Target Recruit Count: 20

Registration Number: NCT00838071

Locations: 🇪🇸
Hospital Virgen del Rocío, Sevilla, Spain
🇪🇸
Hospital Clínic de Barcelona, Barcelona, Spain
🇪🇸
Hospital Vall d'Hebron, Barcelona, Spain

and more 1 locations

Use of Antithrombin in Cardiac Surgery With Cardiopulmonary Bypass

Phase 2

Completed

Conditions: Acquired Antithrombin III Deficiency
Coronary Artery Bypass

Interventions: Drug: Antithrombin III

First Posted Date: 2009-01-15

Last Posted Date: 2016-09-20

Lead Sponsor: Instituto Grifols, S.A.

Target Recruit Count: 200

Registration Number: NCT00823082

Locations: 🇮🇹
IRCCS Policlinico San Donato, Milano, Lombardy, Italy

Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid

Phase 2

Completed

Conditions: Alzheimer's Disease

Interventions: Other: Control
Biological: Albutein 5%

First Posted Date: 2008-08-27

Last Posted Date: 2016-06-14

Lead Sponsor: Instituto Grifols, S.A.

Target Recruit Count: 42

Registration Number: NCT00742417

Locations: 🇺🇸
Mid-Atlantic Geriatric/ARC, Manchester Township, New Jersey, United States
🇪🇸
Hospital General Universitario Gregorio Marañon, Madrid, Spain
🇪🇸
Fundació ACE, Barcelona, Catalunya, Spain

and more 1 locations

Clinical Trial in Patients Diagnosed With Immune Thrombocytopenic Purpura

Phase 3

Completed

Conditions: Immune (Idiopathic) Thrombocytopenic Purpura

Interventions: Biological: IGIV3I Grifols

First Posted Date: 2008-06-17

Last Posted Date: 2016-02-08

Lead Sponsor: Instituto Grifols, S.A.

Target Recruit Count: 18

Registration Number: NCT00699140

Locations: 🇷🇺
Federal Research Clinical Centre of Pediatric Hematology, Oncology and Immunology Roszdrava, Moscow, Russian Federation
🇷🇺
Haematology Research Centre of Russian Academy of Medical Science, Moscow, Russian Federation
🇪🇸
Hospital General Vall d´Hebron, Barcelona, Spain

and more 4 locations

Safety and Efficacy Study of Fibrin Sealant Grifols Evaluated as an Adjunct to Hemostasis

Phase 2

Completed

Conditions: Target Bleeding Site During Peripheral Vascular Surgery

Interventions: Procedure: Manual Compression
Biological: FS Grifols

First Posted Date: 2008-05-26

Last Posted Date: 2016-01-25

Lead Sponsor: Instituto Grifols, S.A.

Target Recruit Count: 239

Registration Number: NCT00684047

Locations: 🇨🇦
Jewish General Hospital, Montreal, Quebec, Canada
🇨🇦
Royal Victoria Hospital, Montreal, Quebec, Canada
🇬🇧
Frimley Park Hospital, Frimley, Surrey, United Kingdom

and more 16 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy